Conflict of Interest Concerns Raised Over Pharmaceutical Marketing Regulatory Panel

A civil society advocacy organisation, the Working Group on Access to Medicines and Treatments, has submitted a formal representation to the Department of Pharmaceuticals objecting to the inclusion of a private hospital network's managing director in an official review committee. The panel was established pursuant to directives from the Supreme Court to evaluate the regulatory architecture governing drug promotion and marketing, specifically the voluntary Uniform Code for Pharmaceutical Marketing Practices (UCPMP), 2024.

Core Governance and Ethical Dimensions

The representation underscores vital governance and public administration principles relevant to health policy and institutional integrity:

• Institutional Neutrality and Conflict of Interest: Advisory bodies entrusted with shaping public health rules must maintain impartiality. The advocacy group argued that direct commercial associations and financial stakes in the corporate hospital sector pose serious potential conflicts of interest, potentially undermining public confidence in regulatory recommendations.
• Regulation of Pharmaceutical Practices: The committee has been tasked with assessing marketing guidelines under the voluntary UCPMP, 2024. Clear, enforceable norms are critical to curb unethical promotional incentives and maintain transparency between drug manufacturers, healthcare providers, and patients.
• Scrutiny Over Healthcare Pricing: The advocacy group pointed to regulatory reviews, including scrutiny by the National Pharmaceutical Pricing Authority (NPPA) and assessments by state drug regulatory bodies in Maharashtra, Uttar Pradesh, and Karnataka, which examined high markups and billing practices in private healthcare institutions.
• Safeguarding Public Interest: The group emphasised that while multi-stakeholder consultations remain valuable, regulatory reform committees constituted under judicial directions must remain free of commercial bias so that public health priorities and access to affordable care take precedence over industry interests.